113 related articles for article (PubMed ID: 10454000)
21. Role of platelet activating factor in development of thrombocytopenia and neutropenia in dogs with endotoxemia.
Tsuchiya R; Kyotani K; Scott MA; Nishizono K; Ashida Y; Mochizuki T; Kitao S; Yamada T; Kobayashi K
Am J Vet Res; 1999 Feb; 60(2):216-21. PubMed ID: 10048555
[TBL] [Abstract][Full Text] [Related]
22. Involvement of nitric oxide and eicosanoids in platelet-activating factor-induced haemodynamic and haematological effects in dogs.
Noguchi K; Matsuzaki T; Shiroma N; Ojiri Y; Sakanashi M
Br J Pharmacol; 1996 Jun; 118(4):941-50. PubMed ID: 8799566
[TBL] [Abstract][Full Text] [Related]
23. Role of platelet-activating factor on extravascular lung water after coronary reperfusion in dogs.
Izuoka T; Takayama Y; Sugiura T; Taniguchi H; Tamura T; Kitashiro S; Jikuhara T; Iwasaka T
Jpn J Physiol; 1998 Apr; 48(2):157-61. PubMed ID: 9639551
[TBL] [Abstract][Full Text] [Related]
24. Combined treatment with endothelin- and PAF-antagonists reduces posttransplant lung ischemia/reperfusion injury.
Stammberger U; Carboni GL; Hillinger S; Schneiter D; Weder W; Schmid RA
J Heart Lung Transplant; 1999 Sep; 18(9):862-8. PubMed ID: 10528748
[TBL] [Abstract][Full Text] [Related]
25. Donor administration of PAF antagonist (TCV-309) enhances lung preservation.
Ide S; Kawahara K; Takahashi T; Sasaki N; Shingu H; Nagayasu T; Yamamoto S; Tagawa T; Tomita M
Transplant Proc; 1995 Feb; 27(1):570-3. PubMed ID: 7879103
[No Abstract] [Full Text] [Related]
26. Role of platelet activating factor in ischaemia-reperfusion injury of isolated rabbit hearts: protective effect of a specific platelet activating factor antagonist, TCV-309.
Katoh S; Toyama J; Kodama I; Koike A; Abe T
Cardiovasc Res; 1993 Aug; 27(8):1430-4. PubMed ID: 8221795
[TBL] [Abstract][Full Text] [Related]
27. Platelet activating factor (PAF) inhibitor (TCV-309) reduces caerulein- and PAF-induced pancreatitis. A morphologic and functional study in the rat.
Tomaszewska R; Dembiński A; Warzecha Z; Banaś M; Konturek SJ; Stachura J
J Physiol Pharmacol; 1992 Dec; 43(4):345-52. PubMed ID: 1294265
[TBL] [Abstract][Full Text] [Related]
28. Platelet-activating factor in hepatic ischemia/reperfusion injury. The effects of a PAF antagonist combined with a prostaglandin I2 analogue.
Nishiyama R; Nakamura S; Suzuki S; Baba S
Transplantation; 1993 Jun; 55(6):1261-5. PubMed ID: 8516812
[TBL] [Abstract][Full Text] [Related]
29. Platelet-activating factor (PAF) and PAF acetylhydrolase activity in rat uterus and placenta during the late stages of pregnancy.
Matsubara T; Yasuda K; Johnston JM; Sanezumi M; Okada H; Matsuoka S; Kanzaki H
Biol Reprod; 1997 Apr; 56(4):885-90. PubMed ID: 9096869
[TBL] [Abstract][Full Text] [Related]
30. Effects of a platelet activating factor antagonist on oedema formation following burns.
Ono I; Gunji H; Hasegawa T; Harada H; Kaneko F; Matsuzaki M
Burns; 1993 Jun; 19(3):202-7. PubMed ID: 8507364
[TBL] [Abstract][Full Text] [Related]
31. Interleukin 10 release during endotoxaemia in chimpanzees: role of platelet-activating factor and interleukin 6.
van der Poll T; Jansen J; Levi M; ten Cate H; Hack CE; Aarden LA; ten Cate JW; van Deventer SJ
Scand J Immunol; 1996 Jan; 43(1):122-5. PubMed ID: 8560191
[TBL] [Abstract][Full Text] [Related]
32. Selective signal transduction through the CD3 or CD2 complex is required for class II MHC expression by human T cells.
Oshima S; Eckels DD
J Immunol; 1990 Dec; 145(12):4018-25. PubMed ID: 1979584
[TBL] [Abstract][Full Text] [Related]
33. Effects of TCV-309, a novel PAF antagonist, on circulatory shock and hematological abnormality induced by endotoxin in dogs.
Kawamura M; Kitayoshi T; Terashita Z; Fujiwara S; Takatani M; Nishikawa K
J Lipid Mediat Cell Signal; 1994 May; 9(3):255-65. PubMed ID: 7921785
[TBL] [Abstract][Full Text] [Related]
34. Cardiac functional and structural alterations induced by endotoxin in rats: importance of platelet-activating factor.
Iwase M; Yokota M; Kitaichi K; Wang L; Takagi K; Nagasaka T; Izawa H; Hasegawa T
Crit Care Med; 2001 Mar; 29(3):609-17. PubMed ID: 11373429
[TBL] [Abstract][Full Text] [Related]
35. The platelet activating factor as a pivotal mediator of shock after liver ischemia.
Fukuoka T; Nakajima Y; Nakano H
Surg Today; 1995; 25(4):351-6. PubMed ID: 7633127
[TBL] [Abstract][Full Text] [Related]
36. Induction of IL-4 by platelet-activating factor.
Huang YH; Schäfer-Elinder L; Owman H; Lorentzen JC; Rönnelid J; Frostegård J
Clin Exp Immunol; 1996 Oct; 106(1):143-8. PubMed ID: 8870712
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic potential of platelet-activating factor antagonism in the management of myocardial infarction.
Loucks EB; Qayumi AK; Godin DV; English JC; Lim SP; Al Mahmeed T; Gul S
Can J Cardiol; 2000 Apr; 16(4):497-504. PubMed ID: 10787465
[TBL] [Abstract][Full Text] [Related]
38. The role of platelet-activating factor in regional myocardial ischemia-reperfusion injury.
Qayumi AK; English JC; Godin DV; Ansley DM; Loucks EB; Lee JU; Kim CW
Ann Thorac Surg; 1998 Jun; 65(6):1690-7. PubMed ID: 9647083
[TBL] [Abstract][Full Text] [Related]
39. Immunoregulatory functions of paf-acether. VI. Inhibition of T cell activation via CD3 and potentiation of T cell activation via CD2.
Vivier E; Deryckx S; Wang JL; Valentin H; Peronne C; de Vries JE; Bernard A; Benveniste J; Thomas Y
Int Immunol; 1990; 2(6):545-53. PubMed ID: 1982219
[TBL] [Abstract][Full Text] [Related]
40. Resting porcine T lymphocytes expressing class II major histocompatibility antigen.
Saalmüller A; Weiland F; Reddehase MJ
Immunobiology; 1991 Sep; 183(1-2):102-14. PubMed ID: 1834544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
